News
University of Alabama at Birmingham (UAB) Health System and Humana Sign Agreement, Expanding Humana’s Medicare Advantage Provider Network in Alabama
The University of Alabama at Birmingham (UAB) Health System and Humana, a leading health and well-being company, have signed an in-network agreement, expanding access to care for all Humana
The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.
Eli Lilly and Novo Nordisk are, so far, the kings of the weight-loss gold rush. Thanks to their medicines, Zepbound and Wegovy, billions in new revenue inflows are assured in the near term.
But
Bull Market Buys: 2 Growth Stocks to Own for the Long Haul
Every good thing must come to an end -- and, eventually, the bull market we're experiencing will, too. Long-term investors must prepare for that to happen at some point.
One of the best ways to do
3 No-Brainer Stocks to Buy in June
You're probably familiar with the old adage, "April showers bring May flowers." And you probably know the punchline to the question, "What do May flowers bring?" (The answer: Pilgrims.)
But what
3 Stocks to Buy for Huge Income
When it comes to dividend investing, some investors like to invest for income, and if you are searching for income, this is the video for you. Today, we will be looking at three dividend stocks that
Is Medtronic Stock a Buy?
Medtronic (NYSE: MDT) is a top healthcare company and a leading maker of medical devices. At a market cap of more than $100 billion, the business has soundly established itself in the industry. It
Is Pfizer the Best Dividend Stock for You?
The pandemic-influenced revenue gusher from which pharmaceutical giant Pfizer (NYSE: PFE) benefitted a few years ago has trickled down to a small stream. As a result, share prices have fallen and
Is Pfizer an Excellent Dividend Stock to Buy for Passive Income Investors?
Fool.com contributor Parkev Tatevosian reviews Pfizer (NYSE: PFE) stock for passive income investors.
*Stock prices used were the afternoon prices of May 28, 2024. The video was published on May
Medtronic Stock Is a Sell, According to 1 Wall Street Analyst
One week ago, medical device maker Medtronic (NYSE: MDT) surpassed Wall Street's sales and earnings targets. Despite the earnings beat, and despite giving guidance that mostly matched analysts'
Beat the Dow Jones With This Cash-Gushing Dividend Stock
Since its spinoff from Pfizer in 2013, animal healthcare behemoth Zoetis (NYSE: ZTS) has seen its cash from operations nearly quintuple as a stand-alone company. Powered by a diverse array of animal
This Pharma Stock Is Poised to Keep Outperforming the S&P 500
AstraZeneca (NASDAQ: AZN), recognized as the world's sixth-largest pharmaceutical entity by market capitalization, made a bold proclamation in May 2014. The company set an ambitious goal of
Should Abbott and DexCom Investors Be Worried About Vertex Pharmaceuticals?
Successful investors think about the future by focusing on what the new opportunities might be. They also pay attention to threats that could emerge that might impact the stocks they own. Sometimes
3 Dividend Stocks to Double Up on Right Now
Sometimes, misperceptions can work in investors' favor. When others think the outlook for a stock isn't so great, you can win big if that view is overly pessimistic.
Several stocks that pay
AstraZeneca Just Massively One-Upped Pfizer. Here's What It Means for the Stock
As two of the world's largest and most prolific drugmakers, Pfizer (NYSE: PFE) and AstraZeneca (NASDAQ: AZN) both have grand visions for how to grow even larger over the coming years. And with
Where Will Amgen Be in 3 Years?
If you're looking for an investment in the pharmaceutical sector and you don't already own shares of Amgen (NASDAQ: AMGN), it might be worth considering a purchase. The company's development of
AstraZeneca Plans to Rake in $80 Billion by 2030. Should You Buy the Stock?
AstraZeneca (NASDAQ: AZN) is embarking on a fresh business plan that will see it grow significantly between now and 2030. If it succeeds, it'll be a company that's even more prominent in the global
2 Beaten-Down Dividend Stocks Near 52-Week Lows. Should You Buy the Dips?
Does the stock market feel overbought to you? After watching the benchmark S&P 500 index climb about 28% over the past year, nobody can blame value-conscious investors for thinking twice before
Got $500? 3 Pharma Stocks to Buy and Hold Forever
A sum of $500 might not seem like much of an investment, but if you select the right pharmaceutical stocks -- and are patient enough to hold them forever -- history shows you'll have a very high
Is It Too Late to Buy Vertex Pharmaceuticals Stock?
Vertex Pharmaceuticals (NASDAQ: VRTX) is a fast-growing pharmaceutical company that investors have been bullish on for years. The business generates billions in revenue from cystic fibrosis drugs
3 Reasons to Buy CRISPR Therapeutics Stock Like There's No Tomorrow
As its shareholders already know, CRISPR Therapeutics (NASDAQ: CRSP) has quite a few opportunities on the table. Between its commercialized medicine, a pipeline that's packed with chances to mint
Forget Nvidia, Buy This Magnificent Healthcare Stock Instead
Nvidia (NASDAQ: NVDA) has been a great stock to own, and it could remain that way for long-term investors. However, the problem is that it's trading at nearly 40 times its future profits. At such a
Amgen's Catching Up to Novo Nordisk and Eli Lilly. Should You Buy It?
With some promising clinical trial results in hand and more that could be on the way relatively soon, Amgen's (NASDAQ: AMGN) latest attempt to develop a therapy for obesity is looking like it could
Want $1,000 in Dividend Income? Here's How Much You'd Have to Invest in CVS Stock.
CVS Health (NYSE: CVS) is one of the most influential healthcare companies in the country.
It operates the nation's largest pharmacy chain, a massive pharmacy benefit management business, and the
How Much Will Pfizer Pay Out in Dividends This Year?
A vaccine and an antiviral treatment for COVID-19 made Pfizer (NYSE: PFE) a household name in recent years, but this isn't all the company sells. There are dozens of innovative medicines in its
Medtronic Stock Could Soar 29%, According to a Wall Street Analyst. Is the Dividend Champion a Buy Now?
Shares of Medtronic (NYSE: MDT) responded poorly to the company's latest quarterly results announcement. The market knocked the stock about 5% lower on May 23, but some analysts who follow the